VIA
JANX icon

Virtus Investment Advisers’s Janux Therapeutics JANX Stock Holding History

Virtus Investment Advisers’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$371K Buy
24,130
+6,309
+35% +$91.4K 0.09% 327
2026
Q1 		$248K Buy
17,821
+433
+2% +$5.94K 0.07% 316
2025
Q4 		$240K Buy
17,388
+12,936
+291% +$304K 0.07% 346
2025
Q3 		$109K Buy
4,452
+773
+21% +$18.8K 0.03% 415
2025
Q2 		$85K Buy
3,679
+1,011
+38% +$26.6K 0.03% 403
2025
Q1 		$72K Buy
+2,668
New +$101K 0.02% 452

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Virtus Investment Advisers's JANX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Janux Therapeutics (JANX) stake by 35% in Q2 2026, buying an estimated $91.4K and bringing the position to 24,130 shares worth $371K. The position accounts for 0.09% of the portfolio, ranked #327.

Virtus Investment Advisers first reported a position in JANX in Q1 2025 and has held it in 6 quarters since. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Virtus Investment Advisers held 24,130 shares of Janux Therapeutics worth $371K as of Q2 2026.
  • Virtus Investment Advisers bought 6,309 Janux Therapeutics shares in Q2 2026, an estimated $91.4K.
  • Janux Therapeutics made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #327 holding.
  • Virtus Investment Advisers first reported a position in Janux Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.